PMN ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. (PMN) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: August 5, 2026 , by Kaplan Johanne .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Kaplan Johanne | Chief Development Officer | Buy | 2,280 | $13.30 | $30.3K | 6,221 | |
| Kirwin Patrick D. | Director | Buy | 4,000 | $11.33 | $45.3K | 4,653 | |
| Williams Eugene | Director | Buy | 2,000 | $24.40 | $48.8K | 12,397 | |
| Williams Eugene | Director | Buy | 2,000 | $24.00 | $48.0K | 10,397 | |
| Williams Eugene | Director | Buy | 1,000 | $21.89 | $21.9K | 8,397 | |
| Williams Eugene | Director | Buy | 1,000 | $22.53 | $22.5K | 7,397 | |
| Kaplan Johanne | Chief Development Officer | Buy | 1,629 | $15.35 | $25.0K | 3,941 | |
| Buy | 700,741 | $12.13 | $8.5M | 943,090 | |||
| Milbury Max A. | Other | Buy | 30,392 | $0.49 | $14.9K | 45,389 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.